Bladder Cancer Clinical Trials
Pfizer C5701009 EV-309:
Phase 3, Open-Label, Randomized Study to Evaluate Enfortumab Vedotin In Combination with Pembrolizumab In Adult Participants with Muscle-Invasive Bladder Cancer Who Are Ineligible For Or Have Elected Not To Undergo Cystectomy.